Track the ArriVent Biopharma, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.4bn. The latest transaction was filed on 3 February 2026 (Cession). Among the most active insiders: LaChapelle Robin. Every trade is openly available.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€11m
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ArriVent Biopharma, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$44.60.
15Σ signal
Buys n/a€11m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
ArriVent Biopharma, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades respiratorias. Cotiza en NASDAQ bajo el ticker XNAS.